Adial Pharmaceuticals Inc
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing treatments for addiction, including alcohol use disorder (AUD) and other addictive disorders such as opioid use disorder, gambling, and obesity. The company's lead drug candidate, AD04, is a genetically targeted therapeutic agent currently under clinical development, with plans to advance to Phase 3 trials. The company emphasizes its strong intellectual property portfolio, strategic collaborations, and commitment to addressing a significant unmet medical need in addiction treatment. Adial aims to become a leading player in the war on addiction by leveraging its proprietary genetic tests, expanding its patent estate, and engaging with global thought leaders and regulatory agencies.
Industries
Nr. of Employees
small (1-50)
Adial Pharmaceuticals Inc
Products
Genotype-targeted oral small-molecule investigational therapeutic
An investigational oral small-molecule therapeutic developed for treatment of addictive disorders in genetically defined patient subgroups; progressed through Phase 2b and advanced toward Phase 3 evaluation.
Companion diagnostic genetic assay for patient stratification
A genetic marker–based assay designed to identify target genotypes to enable genotype-guided enrollment in clinical trials and to support future precision prescribing.
Genotype-targeted oral small-molecule investigational therapeutic
An investigational oral small-molecule therapeutic developed for treatment of addictive disorders in genetically defined patient subgroups; progressed through Phase 2b and advanced toward Phase 3 evaluation.
Companion diagnostic genetic assay for patient stratification
A genetic marker–based assay designed to identify target genotypes to enable genotype-guided enrollment in clinical trials and to support future precision prescribing.
Services
Sponsor-led planning and operational management of late-stage clinical trials including protocol coordination, CRO oversight, investigator network coordination, genotype-based enrollment strategies, and regulatory liaison.
Sponsor-led planning and operational management of late-stage clinical trials including protocol coordination, CRO oversight, investigator network coordination, genotype-based enrollment strategies, and regulatory liaison.
Expertise Areas
- Genotype-guided therapeutic development
- Pharmacogenetic clinical trial design and execution (Phase 2/3)
- Multinational clinical program and CRO management
- CMC development and GMP clinical manufacturing coordination
Key Technologies
- Genetic biomarker-based patient stratification
- Companion diagnostic genetic assays
- Pharmacogenetic clinical trial methodology
- Small-molecule therapeutics targeting 5-HT3 receptor mechanisms
News & Updates
Adial Pharmaceuticals announced agreements with Cambrex and Thermo Fisher Scientific to provide manufacturing services for its drug candidate AD04, supporting US clinical trials and NDA submission.
An article discussing the challenges faced by Adial Pharmaceuticals' new CEO Cary Claiborne, including mixed trial results and economic conditions, and lessons learned from GE.
Adial Pharmaceuticals announced its participation at the 2019 Wall Street Conference, highlighting its ongoing developments and strategic plans.
Adial announced its participation in the 2024 ThinkEquity Conference, including a webcast presentation.
Adial celebrated its IPO and Nasdaq listing by ringing the opening bell at Times Square.
Adial reported on its activities, including IPO, clinical progress, and patent developments.
Adial Pharmaceuticals announced agreements with Cambrex and Thermo Fisher Scientific to provide manufacturing services for its drug candidate AD04, supporting US clinical trials and NDA submission.
An article discussing the challenges faced by Adial Pharmaceuticals' new CEO Cary Claiborne, including mixed trial results and economic conditions, and lessons learned from GE.
Adial Pharmaceuticals announced its participation at the 2019 Wall Street Conference, highlighting its ongoing developments and strategic plans.
Adial announced its participation in the 2024 ThinkEquity Conference, including a webcast presentation.
Adial celebrated its IPO and Nasdaq listing by ringing the opening bell at Times Square.
Adial reported on its activities, including IPO, clinical progress, and patent developments.